📊 VNOV Key Takeaways
Is VitaNova Life Sciences Corp (VNOV) a Good Investment?
VitaNova demonstrates exceptional 366.5% YoY revenue growth with strong operating profitability and robust cash generation (386.1K FCF from 1.2M revenue). The company maintains an excellent balance sheet with 5.05x current ratio and zero debt, positioning it well for continued growth despite temporary net losses that appear scale-related.
Why Buy VitaNova Life Sciences Corp Stock? VNOV Key Strengths
- Exceptional revenue growth of 366.5% YoY indicating strong market traction
- Strong cash generation with 31.1% FCF margin and positive operating cash flow
- Excellent liquidity position with 5.05x current ratio and 52% cash-to-assets ratio
- Zero debt burden with healthy 52.1% gross margins and positive operating income
VNOV Stock Risks: VitaNova Life Sciences Corp Investment Risks
- Currently unprofitable at net income level (-54.9K loss) despite operating gains
- Extremely small company size ($2.3M assets) with limited economies of scale
- Sector classification mismatch: SIC 5130 (wholesale apparel) conflicts with company name (Life Sciences)
- Zero insider activity in past 90 days suggests limited management conviction
- Substantial gap between operating income and net income requires clarification
Key Metrics to Watch
- Path to net profitability and timing of sustainable positive earnings
- Revenue growth sustainability and whether 366% growth rate is repeatable
- Operating cash flow consistency and free cash flow per dollar of revenue
VitaNova Life Sciences Corp (VNOV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 31.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.05x current ratio provides a solid financial cushion.
VNOV Profit Margin, ROE & Profitability Analysis
VNOV vs Consumer Sector: How VitaNova Life Sciences Corp Compares
How VitaNova Life Sciences Corp compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VitaNova Life Sciences Corp Stock Overvalued? VNOV Valuation Analysis 2026
Based on fundamental analysis, VitaNova Life Sciences Corp has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VitaNova Life Sciences Corp Balance Sheet: VNOV Debt, Cash & Liquidity
VNOV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VitaNova Life Sciences Corp's revenue has grown significantly by 366% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.01 reflects profitable operations.
VNOV Revenue Growth, EPS Growth & YoY Performance
VNOV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $308.3K | $32.6K | $0.01 |
| Q2 2026 | $292.1K | -$10.5K | $0.00 |
| Q1 2026 | $103.9K | -$46.3K | $0.00 |
| Q3 2025 | $26.1K | $5.9K | $0.00 |
| Q2 2025 | N/A | -$8.8K | $0.00 |
| Q1 2025 | N/A | -$24.2K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VitaNova Life Sciences Corp Dividends, Buybacks & Capital Allocation
VNOV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VitaNova Life Sciences Corp (CIK: 0001699709)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VNOV
What is the AI rating for VNOV?
VitaNova Life Sciences Corp (VNOV) has an AI rating of BUY with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VNOV's key strengths?
Claude: Exceptional revenue growth of 366.5% YoY indicating strong market traction. Strong cash generation with 31.1% FCF margin and positive operating cash flow.
What are the risks of investing in VNOV?
Claude: Currently unprofitable at net income level (-54.9K loss) despite operating gains. Extremely small company size ($2.3M assets) with limited economies of scale.
What is VNOV's revenue and growth?
VitaNova Life Sciences Corp reported revenue of $1.2M.
Does VNOV pay dividends?
VitaNova Life Sciences Corp does not currently pay dividends.
Where can I find VNOV SEC filings?
Official SEC filings for VitaNova Life Sciences Corp (CIK: 0001699709) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VNOV's EPS?
VitaNova Life Sciences Corp has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VNOV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, VitaNova Life Sciences Corp has a BUY rating with 65% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is VNOV stock overvalued or undervalued?
Valuation metrics for VNOV: ROE of -3.0% (sector avg: 18%), net margin of -4.4% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy VNOV stock in 2026?
Our dual AI analysis gives VitaNova Life Sciences Corp a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VNOV's free cash flow?
VitaNova Life Sciences Corp's operating cash flow is $386.1K, with capital expenditures of N/A. FCF margin is 31.1%.
How does VNOV compare to other Consumer stocks?
Vs Consumer sector averages: Net margin -4.4% (avg: 8%), ROE -3.0% (avg: 18%), current ratio 5.05 (avg: 1.5).